Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study examines if a preoperative stellate ganglion block (SGB) combined with intraoperative dexmedetomidine (DEX) can improve postoperative sleep quality and reduce pain and adverse events after laparoscopic gynecologic procedures. Participants are women aged 18-75 with ASA I-III who are scheduled for laparoscopic hysterectomy or fibroid-related surgery. The design includes a DEX infusion, SGB, and placebo/sham controls to evaluate potential interaction effects and overall efficacy, safety, and cost-effectiveness. Outcomes focus on sleep disturbance, emergence from anesthesia, recovery pace, and hospital stay. The setting is Huai'an, China, under lead sponsor Catherine Zhang.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with American Society of Anesthesiologists (ASA) physical status I-III;
2. Age 18-75 years;
3. Scheduled to undergo laparoscopic gynecologic surgery (laparoscopic hysterectomy or laparoscopic surgery for uterine fibroids).

Exclusion Criteria:

1. Preoperative sore throat or hoarseness;
2. History of upper respiratory tract infection within the previous 2 weeks;
3. Anticipated difficult tracheal intubation (Mallampati class III or IV, potential facial deformity, mouth opening \<3 finger breadths, etc.);
4. Severe preoperative cardiac, hepatic, renal, or other organ dysfunction;
5. Allergy to the local anesthetic used in the study, infection at the puncture site, or coagulation abnormalities;
6. Cognitive impairment, hearing impairment, language impairment, a history of psychiatric illness, or difficulty communicating or cooperating because of a psychiatric disorder.

Where it's running

• Huai'an Second People's Hospital
  Huai'an, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Jun Wang
• Email: 1961440528@qq.com
• Phone: +86 19552153837

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two types of sutures for vaginal cuff closure in laparoscopic hysterectomy

  This study is testing whether a new type of suture can close the vaginal cuff faster than a standard suture for women having laparoscopic hysterectomy, without causing more complications.

  Recruiting at 2 sites Aesculap AG · Frankfurt am Main, Hesse and 1 other locations · NCT06024109

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.